Supernus Pharmaceuticals (SUPN) has drawn fresh attention as investors reassess its role in treating central nervous system conditions, with returns over the past year and multi year period prompting closer scrutiny of its current valuation.

Recent trading has been relatively steady, with a 90 day share price return of 4.44% and a 1 year total shareholder return of 60.73%, suggesting momentum has been building over time from a higher base.

If Supernus has sharpened your interest in healthcare, this is a good moment to scout other opportunities in AI driven medicine and review the 34 healthcare AI stocks

With Supernus showing revenue growth of 12.69% alongside a net loss of US$38.55m, and trading below some analyst price targets, the key question is whether the current price still leaves room for further upside or already reflects potential future gains.

Most Popular Narrative: 20.2% Undervalued

At a last close of $50.39 versus a narrative fair value of $63.17, the current price sits below what the most followed model suggests, putting the focus on whether the growth path outlined can support that gap.

Expanding patient pool for core products, Qelbree and GOCOVRI, driven by increased prevalence and diagnosis of CNS disorders, as well as broader healthcare access (especially among Medicare patients, as seen with GOCOVRI’s prescription growth), is likely to sustain robust top-line revenue growth.

Commercial infrastructure and recent launch of ONAPGO position Supernus to capture further market share in Parkinson’s disease, benefiting from demographic aging and rising CNS disease burden, which should materially boost revenue and improve gross margins as fixed costs are leveraged.

Curious what kind of revenue trajectory, margin lift, and future earnings multiple would justify a fair value well above today’s price? The narrative sets out a detailed growth path, ties it to product uptake and pipeline timing, and leans on one valuation multiple that is well above the broader sector. Want to see which specific assumptions have to hold for that upside case to work on paper?

Result: Fair Value of $63.17 (UNDERVALUED)

However, the story also depends on Qelbree and GOCOVRI continuing to carry a large share of revenue, and on R&D spending not weighing too heavily on profits.

Next Steps

Given this mix of upside potential and clear risks, it makes sense to review the numbers yourself and decide how comfortable you are with the trade off. To see both sides laid out in one place, take a look at the 4 key rewards and 1 important warning sign

Ready to hunt for your next opportunity?

If Supernus has sharpened your focus, do not stop here. Use the Simply Wall St screener to quickly surface other ideas that might fit your portfolio.

• Target potential mispricings by reviewing companies that appear cheap on quality metrics with the 54 high quality undervalued stocks
• Prioritize resilience by checking out companies that screen well on stability and risk with the 74 resilient stocks with low risk scores
• Spot under followed names with solid fundamentals using the screener containing 23 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.